LAUSR

Micro‐Abstract A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in this randomized, placebo‐controlled phase trial of 537 patients with advanced HER2‐negative breast cancer, we found that the combination of sorafenib with capecitabine did not improve progression‐free survival, overall survival, or overall response rate, but increased treatment‐related toxicities and discontinuations. Introduction: Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. In this randomized, double‐blind, placebo‐controlled phase III trial, we assessed first‐ or second‐line capecitabine with sorafenib or placebo in patients with locally advanced/metastatic HER2‐negative breast cancer resistant to a taxane and anthracycline and with known estrogen/progesterone receptor status. Patients and Methods: A total of 537 patients were randomized to capecitabine 1000 mg/m2 orally twice per day for days 1 to 14 every 21 days with oral sorafenib 600 mg/d or placebo. The primary end point was progression‐free survival (PFS). Patients were stratified according to hormone receptor status, previous chemotherapies for metastatic breast cancer, and geographic region. Results: Treatment with sorafenib with capecitabine, compared with capecitabine with placebo, did not prolong median PFS (5.5 vs. 5.4 months; hazard ratio [HR], 0.973; 95% confidence interval [CI], 0.779‐1.217; P = .811) or overall survival (OS; 18.9 vs. 20.3 months; HR, 1.195; 95% CI, 0.943‐1.513; P = .140); or enhance overall response rate (ORR; 13.5% vs. 15.5%; P = .515). Any grade toxicities (sorafenib vs. placebo) included palmar‐plantar erythrodysesthesia syndrome (PPES; 79.2% vs. 59.6%), diarrhea (47.3% vs. 37.8%), mucosal inflammation (15.4% vs. 6.7%), and hypertension (26.2% vs. 5.6%). Grade 3/4 toxicities included PPES (15.4% vs. 7.1%), diarrhea (4.2% vs. 6.4%), and vomiting (3.5% vs. 0.7%). Conclusion: The combination of sorafenib with capecitabine did not improve PFS, OS, or ORR in patients with HER2‐negative advanced breast cancer. Rates of Grade 3 toxicities were higher in the sorafenib arm. Graphical abstract: Compared with capecitabine with placebo, capecitabine with sorafenib did not significantly prolong progression‐free survival in patients with HER2‐negative advanced/metastatic breast cancer. Figure. No Caption available.